S. Schulman et al., INFLUENCE OF CHANGES IN LIFE-STYLE ON FIBRINOLYTIC PARAMETERS AND RECURRENCE RATE IN PATIENTS WITH VENOUS THROMBOEMBOLISM, Blood coagulation & fibrinolysis, 6(4), 1995, pp. 311-316
A prospective, non-randomized, interventional study was carried out to
evaluate the effect of changes in lifestyle on abnormal fibrinolytic
parameters, and the influence of those, in turn, on the risk of recurr
ence among patients with venous thromboembolism. Patients with elevate
d plasminogen activator inhibitor 1 (PAI-1) levels or decreased releas
e of tissue plasminogen activator (t-PA) antigen were given informatio
n and advice about improved diet, increased physical activity, weight
loss and/or cessation of smoking. Totally 144 patients (119 with eleva
ted PAI-1 and 25 with deficient t-PA release) were followed with repea
ted analyses of the fibrinolytic parameters for a median of 8 months a
fter the initial advice, and 65% of the patients managed to execute at
least one change in their lifestyle. The reduction of PAI-1 activity
after one, two and three changes in lifestyle were -2.4, -10.0 and -14
.0 AU/ml (-10, -30 and -48% of baseline activity), respectively. Those
who accomplished two or three changes in their lifestyle had a greate
r chance of normalizing the PAI-1 level than those with no or only one
change (P = 0.009). The effects of improved diet, weight loss and inc
reased physical activity on the PAI-1 level were of a similar magnitud
e, -7.0 to -10.4 AU/ml (24-32% reduction). The effect on t-PA release
was more difficult to evaluate due to the limited number of those pati
ents. After a follow-up of 6 years (mean) after the first visit the pa
tients were enquired about recurrent events, with a response rate of 8
6%. There was no detectable effect of the improvement of PAI-1 levels
on the risk of recurrent thromboembolism. Thus, although it is possibl
e to modify the abnormalities in the fibrinolytic parameters through c
hanges in lifestyle, this in turn will not have any remarkable effect
on the risk of new thromboembolic events in patients with initial veno
us thromboembolism.